PaxVax announces three new officers
The Menlo Park, Calif.-based company, has grants and contracts for the development of vaccines for anthrax and HIV, in addition to the characterization of a novel cell substrate, A549, for the production of vaccines, the San Francisco Business Times reports.
PaxVax, which is preparing its lead cholera vaccine for Phase III trials, also has a Phase II clinical trial of a pandemic H5N1 influenza vaccine using its proprietary adenoviral-based technology.
The company hired Nima Farzan as its chief operating officer and executive vice president, Thomas Monath as its chief technology officer and Jonathan Smith as chief scientific officer and executive vice president, the San Francisco Business Times reports.
Farzan was most recently the vice president of marketing for Novartis Vaccines USA. Monath worked for the venture capital firm Kleiner Perkins Caufield & Byers and was a partner in its pandemic and biodefense fund. Smith previously served as the chief scientific officer at Liquidia.
PaxVax has raised more than $50 million from Ignition Partners and Wellcome Trust since the company was founded in 2007. PaxVax also has support from the Bill and Melinda Gates Foundation and grants from the National Institutes of Health.